Pharmacogenetic-based clinical scores: a useful, simple tool to predict tamoxifen-based CYP2D6 phenotype?

about

Deriving rules and assertions from pharmacogenomics knowledge resources in support of patient drug metabolism efficacy predictions.

P2860

Q36175128-15BB9178-A764-4E7C-9C45-9E0CACF41F7B

P2860

Pharmacogenetic-based clinical scores: a useful, simple tool to predict tamoxifen-based CYP2D6 phenotype?

Item

http://www.wikidata.org/entity/Q43188221

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Pharmacogenetic-based clinical ...... oxifen-based CYP2D6 phenotype?

@en

Pharmacogenetic-based clinical ...... oxifen-based CYP2D6 phenotype?

@nl

type

Item

label

Pharmacogenetic-based clinical ...... oxifen-based CYP2D6 phenotype?

@en

Pharmacogenetic-based clinical ...... oxifen-based CYP2D6 phenotype?

@nl

prefLabel

Pharmacogenetic-based clinical ...... oxifen-based CYP2D6 phenotype?

@en

Pharmacogenetic-based clinical ...... oxifen-based CYP2D6 phenotype?

@nl

P1476

Pharmacogenetic-based clinical ...... oxifen-based CYP2D6 phenotype?

@en

P2093

Uwe Fuhr

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.

Target concentration intervention: beyond Y2K.

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.

Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach.

Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.

Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration

Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.

Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.

P304

370-372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1177/0091270009353605

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20089828

http://www.w3.org/2001/XMLSchema#string

Pharmacogenetic-based clinical scores: a useful, simple tool to predict tamoxifen-based CYP2D6 phenotype?

about

P2860

P2860

Pharmacogenetic-based clinical scores: a useful, simple tool to predict tamoxifen-based CYP2D6 phenotype?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698